Management and outcomes for patients with TTP: Analysis of 100 cases at a single institution

American Journal of Hematology

Volumn 88, Issue 7, 2013, Pages 560-565

  Chaturvedi, Shruti ^a   Carcioppolo, Desiree ^b   Zhang, Li ^a   Mccrae, Keith R ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTATE DEHYDROGENASE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGE; ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENCE RISK; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; ADOLESCENT; ADULT; AGE FACTORS; AGED; DISEASE MANAGEMENT; DISEASE PROGRESSION; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84879378089     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23455     Document Type: Article

References (37)

1. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991;325:398-403.
2. Hovinga J, Vesely S, Terrell D, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115:1500-1511.
3. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995;122:569-572.
4. Cataland SR, Jin M, Ferketich AK, et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2007;136:146-149.
5. Ziman A, Mitri M, Klapper E, et al. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: One institution's experience and review of the literature. Transfusion 2005;45:41.
6. Honda K, Hidaka S, Kobayashi S. Successful treatment with cyclosporine of thrombotic thrombocytopenic purpura refractory to corticosteroids and plasma exchange. Ther Apher Dial 2011;15:215-217.
7. Chemnitz JM, Uener J, Hallek M, Scheid C. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol 2010;89:1029-1033.
8. Sadler J. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 112:11-11-18.
9. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood 2005;106:1932-1937.
10. Heidel F, Lipka DB, von Auer C, et al. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 2007;97:228-233.
11. de la Rubia J. Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study. Transfus Apher Sci 2010;43:299-299-303.
12. Scully M, McDonald V, Cavenagh J, et al. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011;118:1746-1753.
13. Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003;102:60-68.
14. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223-1229.
15. Dierkes F, Andriopoulos N, Sucker C, et al. Indicators of acute and persistent renal damage in adult thrombotic microangiopathy. PLoS One 2012;7:e30886.
16. Dervenoulas J, Tsirigotis P, Bollas G, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol 2000;79:66-72.
17. Sarode R, Gottschall JL, Aster RH, McFarland JG. Thrombotic thrombocytopenic purpura: Early and late responders. Am J Hematol 1997;54:102-107.
18. Liu C, Kallogjeri D, Dynis M, Grossman BJ. Platelet recovery rate during plasma exchange predicts early and late responses in patients with thrombotic thrombocytopenic purpura. Transfusion 2012 [Epub ahead of print].
19. Hollenbeck M, Kutkuhn B, Aul C, et al. Haemolytic-uraemic syndrome and thrombotic-thrombocytopenic purpura in adults: Clinical findings and prognostic factors for death and end-stage renal disease. Nephrol Dial Transplant 1998;13:76-81.
20. Levandovsky M, Harvey D, Lara P, Wun T. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): A 24-year clinical experience with 178 patients. J Hematol Oncol 2008;1:23.
21. Austin PC, Tu JV. Bootstrap methods for developing predictive models. Am Stat 2004;58:131-137.
22. George JN, Vesely SK, Terrell DR. The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: A community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 2004;41:60-67.
23. Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: Correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008;142:819-826.
24. Jang MJ, Chong SY, Kim IH, et al. Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: The Korean TTP registry experience. Int J Hematol 2011;93:163-169.
25. George JN. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003;10:339-344.
26. Stirling Y, Woolf L, North WR, et al. Haemostasis in normal pregnancy. Thromb Haemost 1984;52:176-182.
27. de Moerloose P, Amiral J, Vissac AM, Reber G. Longitudinal study on activated factors XII and VII levels during normal pregnancy. Br J Haematol 1998;100:40-44.
28. Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001;98:2730-2735.
29. Zhan H, Streiff MB, King KE, Segal JB. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: Clinical outcomes and risk factors for relapse. Transfusion 2010;50:868-874.
30. Benhamou Y, Assie C, Boelle PY, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: The French TMA Reference Center experience. Haematologica 2012;97:1181-1186.
31. Ramanan AS, Thirumala S, Chandrasekaran V. Thrombotic thrombocytopenia purpura: A single institution experience. J Clin Apher 1999;14:9-13.
32. Wyllie BF, Garg AX, Macnab J, et al. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: A new index predicting response to plasma exchange. Br J Haematol 2006;132:204-209.
33. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Frequency, clinical features, and long-term outcomes. Ann Intern Med 2001;135:1047-1051.
34. Reti M, Farkas P, Csuka D, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012;10:791-798.
35. Ren G, Hack BK, Minto AW, et al. A complement-dependent model of thrombotic thrombocytopenic purpura induced by antibodies reactive with endothelial cells. Clin Immunol 2002;103:43-53.
36. Chapin J, Weksler B, Magro C, Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012;157:772-774.
37. Nguyen L, Terrell DR, Duvall D, et al. Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008. Transfusion 2009;49:392-394.